Skip to main content

CD30-Positive Neoplastic Cells Present clinical trials at UC Davis
1 research study open to eligible people

  • An Experimental Combination of Brentuximab, Vedotin or Crizotinib For Anaplastic Large Cell Lymphoma (rare type of blood cancer)

    open to eligible people ages up to 21 years

    This partially randomized phase II trial studies how well brentuximab vedotin or crizotinib and combination chemotherapy works in treating patients with newly diagnosed stage II-IV anaplastic large cell lymphoma. Brentuximab vedotin is a monoclonal antibody, called brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in targeted way and delivers vedotin to kill them. Crizotinib and methotrexate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether brentuximab vedotin and combination chemotherapy is more effective than crizotinib and combination chemotherapy in treating anaplastic large cell lymphoma.

    Sacramento, California and other locations

Last updated: